RELATED STUDY
GPR3 And GPR6, Novel Molecular Targets For Cannabidiol
Key Findings: Study results demonstrate for the first time that both GPR3 and GPR6 are novel molecular targets for CBD. This discovery that CBD acts as a novel inverse agonist on both GPR3 and GPR6 indicates that some of the potential therapeutic effects of CBD (e.g. treatment of Alzheimer's disease and Parkinson's disease) may be mediated through these important receptors.
Type of Study: Laboratory Study
Study Result: Positive
Research Location(s): United States
Year of Pub: 2017
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype III
Receptors Studied: GPCR 3, GPCR 6
Route of Administration: In vitro
Citation: Laun AS and Song ZH. GPR3 and GPR6, novel molecular targets for cannabidiol. Biochem Biophys Res Commun. 2017; 490:17-21. doi: 10.1016/j.bbrc.2017.05.165
Authors: Laun AS, Song ZH
